Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 5,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Lung Cancer Clear all

Conditions: Mesothelioma
Interventions: Cisplatin, Imatinib Mesylate, Pemetrexed, Dexamethasone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7
Interventions: Atezolizumab, Cisplatin, Extrapleural Pneumonectomy, Pemetrexed Disodium, Pleurectomy, Radiation Therapy; Drug · Procedure · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 174
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 121 more

Conditions: Non-small Cell Lung Cancer
Interventions: NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg; Device · Drug
Lead sponsor: NovoCure GmbH; Industry
Eligibility: 22 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 24
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 20 more

Conditions: Lung Cancer
Interventions: CareSTEPS; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Lung Cancer, Stage IV Lung Cancer
Interventions: Stereotactic Body Radiation Therapy, Pembrolizumab; Radiation · Biological
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Lung Cancer
Interventions: carboplatin, etoposide, exisulind; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 81
States / cities: Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ramucirumab, Placebo (for Ramucirumab), Docetaxel; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 97
States / cities: Phoenix, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 93 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: nab-Paclitaxel, Carboplatin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Boynton Beach, Florida • New Orleans, Louisiana • Detroit, Michigan + 5 more

Conditions: Lung Cancer, Driver Mutation
Interventions: Low Dose CT Scan; Diagnostic Test
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1,753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Orange, California

Conditions: Lung Cancer
Interventions: Empathic Communication Skills (ECS) training, Standard of Care participant interaction; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1,232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 12
States / cities: Irvine, California • Miami, Florida • Libertyville, Illinois + 7 more

Conditions: Melanoma, Carcinoma, Non-Small- Cell Lung
Interventions: SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, carboplatin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 23
States / cities: Springdale, Arkansas • Los Angeles, California • San Francisco, California + 18 more

Conditions: Solid Tumors, Head and Neck Cancer, Lung Cancer, UC (Urothelial Cancer)
Interventions: MEDI4736, INCB024360; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 13
States / cities: San Francisco, California • Denver, Colorado • Miami, Florida + 10 more

Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Elironrasib, Daraxonrasib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 23
States / cities: Duarte, California • Orange, California • Sacramento, California + 17 more

Conditions: Cancer of the Head and Neck, Cancer of Lung, Cancer of Esophagus, Cancer of Stomach
Interventions: Enhanced Supportive Care - Status Checks, Enhanced Supportive Care - Referrals; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Advanced Non-Small Cell Lung Cancer
Interventions: Pemetrexed, Carboplatin, Paclitaxel, Bevacizumab; Drug · Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 45
States / cities: Scottsdale, Arizona • Tucson, Arizona • Mission Hills, California + 42 more

Conditions: Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Small Cell Lung, Small Cell Cancer Of The Lung
Interventions: PF-08634404, Chemotherapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 23
States / cities: Duarte, California • Encinitas, California • Irvine, California + 13 more

Conditions: Lung Cancer
Interventions: Integrated Staging for Early Detection of Metastases in Lung Cancer; Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Jacksonville, Florida • Rochester, Minnesota • Charleston, South Carolina

Conditions: Lung Cancer
Interventions: Pembrolizumab; Drug
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Baltimore, Maryland

Conditions: Lung Non-Small Cell Carcinoma
Interventions: Biospecimen Collection, Bronchoscopy with Bronchoalveolar Lavage, Chemoradiotherapy, Computed Tomography, Diagnostic Laboratory Biomarker Analysis, Immune Checkpoint Inhibitor, Nasal Wash and Collection, Quality-of-Life Assessment, Questionnaire Administration, Spirometry; Procedure · Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Interventions: Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel; Biological · Drug
Lead sponsor: Genelux Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 15
States / cities: Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more

Conditions: Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans, Pneumonia
Interventions: etanercept; Drug
Lead sponsor: FDA Office of Orphan Products Development; Federal
Eligibility: 12 Months and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Non-Small Cell Lung Carcinoma
Interventions: Albumin-bound paclitaxel, Paclitaxel, Carboplatin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 1,052 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 31
States / cities: Huntsville, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 27 more

Conditions: Lung Cancer
Interventions: cytology specimen collection procedure, immunoenzyme technique, study of high risk factors; Other · Procedure
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2004
U.S. locations: 5
States / cities: Tampa, Florida • Des Moines, Iowa • Hackensack, New Jersey + 2 more

Conditions: Pancreas Cancer, DVT, Pulmonary Embolism
Interventions: Apixaban; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

CareSTEPS: A Supportive Care Program for the Caregivers of Advanced Lung Cancer Patients

Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer

Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2

Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer

Empathic Communication Skills (ECS) Training

A Study of SEA-CD40 Given With Other Drugs in Cancers

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Real-time Activity Monitoring to Prevent Admissions During RadioTherapy

Study of Participants With Advanced Non-Small Cell Lung Cancer

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Surgical Versus Non-surgical Staging of Lung Cancer

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

Early Detection of Second Lung Cancer in Patients With Stage I Non-small Cell Lung Cancer

Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy